CFPC Accreditation:
This activity has been certified by the College of Family Physicians of Canada for up to 5.5 Mainpro+® Certified Activity credits.
AAFP Accreditation:
Members of the American Academy of Family Physicians are eligible to receive up to 5.5 Prescribed credit hours for attendance at this meeting/event due to a reciprocal agreement with the College of Family Physicians of Canada.
| Time | Topic | Speaker(s) |
|---|---|---|
| 07:00 PM | Welcome and Introductions | |
| 07:10 PM | Gender differences in CV risk factors, disease and management Learning Objectives Recognize sex-related differences in cardiovascular risk, presentation, and treatment outcomes to improve prevention and management. |
Martha Gulati |
| 07:30 PM | Workup and treatment of resistant hypertension Learning Objectives Identify patients with resistant hypertension and evaluate the role of the aldosterone pathway and emerging targeted therapies. |
Nadia Khan |
| 07:50 PM | What you need to know about metabolic dysfunction-associated steatotic liver disease (MASLD) Learning Objectives Recognize the link between MASLD and cardiovascular risk and apply cardiometabolic risk-reduction strategies |
Alnoor Ramji |
| 08:10 PM | HFpEF diagnosis and managment in primary care Learning Objectives Recognize HFpEF in primary care and apply current diagnostic strategies and therapies that improve patient outcomes |
Justin Ezekowitz |
| 08:30 PM | Q&A | |
| 09:00 PM | Closing Comments |
| Time | Topic | Speaker(s) |
|---|---|---|
| 07:00 PM | Welcome and Introductions | |
| 07:10 PM | Detection and management of ATTR in primary care Learning Objectives Identify clinical features that should prompt evaluation for transthyretin amyloidosis and initiate appropriate referral and management pathways |
Margot Davis |
| 07:30 PM | New frontiers: Will CV inflammation be a treatment target? Learning Objectives Evaluate emerging evidence linking inflammation to cardiovascular disease and its potential implications for future patient care |
Shaun Goodman |
| 07:50 PM | GLP-1 therapies: applications in cardiovascular disease Learning Objectives Apply cardiovascular outcomes evidence for GLP-1 receptor agonists to reduce cardiovascular risk in patients with obesity or cardiometabolic disease |
Milan Gupta |
| 08:10 PM | Are we under-treating chronic kidney disease? Learning Objectives Recognize chronic kidney disease in patients at cardiovascular risk and apply evidence-based therapies that reduce cardiovascular events and slow disease progression |
Navdeep Tangri |
| 08:30 PM | Q&A | |
| 09:00 PM | Closing Comments |
| Time | Topic | Speaker(s) |
|---|---|---|
| 07:00 PM | Welcome and Introductions | |
| 07:10 PM | Where does bempedoic acid fit in my practice? Learning Objectives Apply recent evidence to determine when bempedoic acid should be added to lipid-lowering therapy |
Liam Brunham |
| 07:30 PM | Familial Chylomicronemia Syndrome: Recognition and Treatment Learning Objectives Identify patients with severe hypertriglyceridemia suggestive of familial chylomicronemia syndrome and apply appropriate management strategies
|
Daniel Gaudet |
| 07:50 PM | New frontiers: Where will oral PCSK9 inhibitors fit in clinical practice Learning Objectives Evaluate emerging evidence for oral PCSK9-targeting therapies and their potential role in lipid management |
Milan Gupta |
| 08:10 PM | Intensive LDL-C reduction across the spectrum of ASCVD: applying new guidelines to clinical practice Learning Objectives Apply current guidelines and emerging evidence to support intensive LDL-C reduction across the spectrum of ASCVD. |
Marc Sabatine |
| 08:30 PM | Q&A | |
| 09:00 PM | Closing Comments |
